← Human Trials & Peer-Reviewed Studies
Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS)
Plain-language guide to PMID 31703737 (2019): observational study of Teriparatide.
Key Facts
- PMID
- 31703737
- Journal
- Advances in rheumatology (London, England)
- Year
- 2019
- Study type
- Observational Study
- Authors
- Cunha-Borges JL et al. (11 authors)
- DOI
- 10.1186/s42358-019-0088-2
What This Study Did, in Plain Language
What Was Tested
This observational study looks at Teriparatide.
The aim of this article is to describe the baseline clinical characteristics and fracture history of patients who are prescribed teriparatide in normal clinical practice in Latin America.
The researchers conducted a prospective, multinational, observational study (the Asia and Latin America Fracture Observational Study [ALAFOS]) in 20 countries worldwide to assess the incidence of fractures in postmenopausal women with osteoporosis receiving teriparatide as a part of routine clinical practice in a real-world setting.
Why It Was Studied
Osteoporosis is a major healthcare concern in Latin America.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, women only.
In this subregional analysis of the ALAFOS study, the researchers report the clinical characteristics, fracture history, risk factors for osteoporosis, comorbidities, previous osteoporosis therapies and health-related quality of life measures at baseline for patients from the four participant Latin American countries: Argentina, Brazil, Colombia, and Mexico.
What Was Measured
The subject headings attached to it are Argentina, Back Pain, Bone Density, Bone Density Conservation Agents, Brazil, Colombia and Comorbidity.
The authors tagged it with the keywords ALAFOS, Latin America, Observational study, Osteoporosis and Teriparatide.
What This Means in Plain Language
This is an observational study of Teriparatide.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (Advances in rheumatology (London, England)), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.